GSK joins Boehringer and As­traZeneca in cap­ping out-of-pock­et costs for in­halers

GSK will cap out-of-pock­et costs for its in­halers at $35, mak­ing it the third ma­jor drug­mak­er to agree to lim­it pa­tients’ spend­ing amid sig­nif­i­cant US po­lit­i­cal pres­sure over the price of com­mon­ly used med­ica­tions.

In to­tal, nine GSK prod­ucts will have their out-of-pock­et costs capped, ac­cord­ing to the UK com­pa­ny. In ad­di­tion, the whole­sale ac­qui­si­tion cost for Ad­vair Diskus has been re­duced by an av­er­age of 50% and Ad­vair HFA by an av­er­age of 20%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER